ETON insider files Form 144 to sell 41,713 shares valued at $692,645

Rhea-AI Filing Summary

Eton Pharmaceuticals filed a Form 144 notifying the proposed sale of 41,713 shares of its common stock through Raymond James & Associates on the NASDAQ, with an aggregate market value of $692,645 and an approximate sale date of 08/18/2025. The notice lists the securities' acquisition history: seven lots acquired between 12/09/2022 and 12/10/2024 via ESPP payroll purchases and company grants, totaling the units shown. The filer reports no securities sold in the past three months and includes the standard representation that they are not aware of undisclosed material adverse information about the issuer.

Insights

Securities Analyst

TL;DR: Routine insider sale disclosure; modest in size and filed under Rule 144.

The Form 144 documents a proposed public sale of 41,713 common shares valued at $692,645 to be executed by Raymond James on NASDAQ on 08/18/2025. Acquisition details show these shares were obtained through ESPP purchases and grants between 2022 and 2024. The filing includes the required representation that the seller is unaware of undisclosed material adverse information. This appears to be a standard Rule 144 notification rather than an event indicating issuer-specific distress.

Corporate Governance Expert

TL;DR: Disclosure is compliant and provides clear acquisition history for Rule 144 purposes.

The notice supplies itemized acquisition dates, transaction types (ESPP and grants), payment nature, and broker information, meeting disclosure expectations for a Rule 144 sale. The filing also affirms no sales in the prior three months were reported. From a governance and compliance perspective, the document fulfills statutory notice requirements and preserves market transparency around insider dispositions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Raymond James & Associates 880 Carillon Parkway St. Petersburg FL 33716	41713	692645.00	26817535	08/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/09/2022	ESPP	Issuer			3599	12/09/2022	Payroll
Common	06/09/2023	ESPP	Issuer			5859	06/09/2023	Payroll
Common	07/12/2023	Grant	Issuer			10000	07/12/2023	Grant
Common	12/10/2023	ESPP	Issuer			3145	12/10/2023	Payroll
Common	06/10/2024	ESPP	Issuer			5857	06/10/2024	Payroll
Common	07/12/2024	Grant	Issuer			10000	07/12/2024	Grant
Common	12/10/2024	ESPP	Issuer			3253	12/10/2024	Payroll

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does ETON's Form 144 disclose about the proposed sale?

The filing discloses a proposed sale of 41,713 common shares via Raymond James on NASDAQ with aggregate market value $692,645, approximate sale date 08/18/2025.

How were the shares being sold acquired according to the filing?

The shares were acquired in seven lots between 12/09/2022 and 12/10/2024 through ESPP payroll purchases and company grants.

Did the filer report any securities sold in the past three months?

The form states Nothing to Report under securities sold during the past three months.

Which broker is named to execute the proposed sale?

The broker listed is Raymond James & Associates, located at 880 Carillon Parkway, St. Petersburg, FL.

Does the filing include a representation about undisclosed information?

Yes. The signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.